Dihexa — Deep Research (Cognitive & Nootropic)

Published · Researched 2026-09-21

Research file written 2026-09-21. Social-first methodology: community sources weighted before vendor pages.

1. Overview

Dihexa (PNB-0408) is an angiotensin IV derivative — N-hexanoylated, C-terminally amidated tripeptide mimetic, molecular weight 504.67 g/mol (SourcePeptides spec table, 2026). The modifications were engineered to fix native Ang IV's problems: rapid enzymatic degradation and poor blood-brain-barrier penetration; the hexanoyl cap and amidation confer peptidase resistance and lipophilicity, and preclinical models show BBB penetration. It is researched as an HGF/c-Met signaling modulator with remarkable preclinical potency — Washington State University work characterized it as active at picomolar concentrations in HGF/c-Met binding assays — and it is one of the most potent synaptogenic compounds in the preclinical literature.

The 2026 community story: Dihexa is the category's highest-profile "rewiring" compound — preclinical-only, strong folklore, zero human validation. The June-2026 GitHub hukus/llimitless scan flags it as a visible-but-de-ranked frontier hypothesis: big lore, mostly isolated user stories.

2. Social standing

Split verdict. The community narrative runs from "memory retrieval improved after weeks" to no effect, to discontinued-over-mood-changes:

• Medium first-person accounts: one self-experimenter reported context-recall improvement beginning around week three; another reported memory effects but discontinued because of mood swings — the single most-cited failure mode (Medium self-experiment accounts, 2026).
• Evolutionary.org log: a health-improvement log reported zero side effects over two weeks but explicitly questioned the source — vendor trust is a live part of the story.
• ExcelMale discussion: flags no clinical trials, no FDA approval, and theoretical c-Met/cancer-pathway concerns with no evidence proving or excluding harm — the honest scientific fear, stated without alarmism.
• Threads: searches this round returned mainly generic peptide/supplier posts, not strong Dihexa-specific owner reports.
• Recurring praise: "rewiring" language — memory retrieval, contextual recall after multi-week use.
• Recurring complaints / failure modes: mood swings leading to discontinuation; no effect; source-quality doubts.
• Overhyped warnings: any claim of human efficacy, safe dosing, or cancer safety is UNVERIFIED — no human trials exist; all dosing is community folklore (commonly cited 1–10 mg/day orally is not from any research protocol).

3. Social validation — Tier 3 (single-platform/weak signal, explicitly flagged)

• Medium self-experiment accounts (two independent authors): prove real self-experimentation exists and that the response is split (memory benefit vs. mood-swing discontinuation). Proves the community story is genuinely contested, not one-sided marketing.
• Evolutionary.org forum log: proves independent forum-level self-reporting with source skepticism built in.
• ExcelMale thread: proves the safety-concern discussion (c-Met pathway, no trials) is happening in the community, not being suppressed.
• Vendor research guides (SourcePeptides 2026 guide): synthesize the primary preclinical literature (HGF/c-Met, synaptogenesis, picomolar potency). Proves a real preclinical evidence file behind the folklore — but preclinical only.
• Community dataset signal: June-2026 GitHub hukus/llimitless scan flags Dihexa as frontier lore with isolated user stories. Proves anecdote density is low vs. Semax/Selank/Cerebrolysin.
• Missing: no named Facebook Group posts, no Threads owner content, no controlled human data of any kind.

4. Key specs table

5. Pricing (observed 2026-09-21)

Marketplace used range: not observed — report honestly, no used-market data found. Capsule formats carry a large premium over vials (~1.5–2×), which is worth noting since the oral capsule format has no pharmacokinetic validation behind it.

6. What's included / what's needed

• Lyophilized vials ship as powder; reconstitution solution typically sold separately.
• Capsule formats are ready-to-use but cost more and have no absorption data behind them.
• No reconstitution or dosing protocol exists in any research literature; all use protocols are community folklore.

7. Support reality

• COA culture: SourcePeptides advertises lot-specific third-party testing with viewable COA (purity 99.63%, lot 2347 cited); this is the better end of the market.
• Gray-market risk: research-use-only labeling everywhere; the oral capsule market is especially buyer-beware — unknown absorption, unknown excipient interactions, premium pricing for the least-validated format.
• Source skepticism is part of the product story: the Evolutionary.org logger explicitly questioned their own source mid-log, which is healthy community behavior for a compound with no human data.

8. Community verdict

Dihexa is the category's highest-ceiling, lowest-floor bet: a genuinely interesting preclinical synaptogenic mechanism (picomolar HGF/c-Met activity, BBB penetration) wrapped in zero human data, a split anecdote record (weeks-to-benefit vs. mood-swing discontinuation), and a theoretical cancer-pathway question nobody can answer. The community's honest position: powerful folklore, no validation, treat as experimental pharmacology, not a nootropic.

9. Regulatory & safety status

• USA/EU: not FDA or EMA approved; sold as a research chemical not for human use. No clinical trials; no human efficacy or safety data.
• Theoretical risk: c-Met is an oncogenic signaling pathway; ExcelMale community discussion flags theoretical cancer-pathway concerns with no evidence proving or excluding harm — state plainly, do not dismiss and do not inflate.
• Community-reported side effects: mood swings leading to discontinuation (Medium account, 2026); otherwise no systematic safety record exists.

Images

No real product photos available. No Dihexa images were captured in this session (0/8 views present in img/); vendor listing images were not verifiably captured as distinct real photos. Do not treat the absence of photos as a data point about the compound.

Not medical advice. This is community research, not a recommendation. Dihexa is an unapproved research chemical with no human safety data; it is not for human use. Talk to a clinician before considering any peptide.

Named sources

• SourcePeptides spec table — Molecular weight: 504.67 g/mol (2026)
• SourcePeptides, 2026 — Purity claim: ≥99% HPLC-verified, current lot 2347 cited at 99.63% — vendor claim (2026)
• WSU preclinical work — Mechanism (preclinical): HGF/c-Met signaling modulation; synaptogenesis; picomolar potency in binding assays
• Forum logs — Community-cited dose: 1–10 mg/day oral (folklore) — not medical guidance, no research basis
• Evolutionary.org forum — proves independent forum-level self-reporting with source skepticism built in.
• SourcePeptides guide — synthesize the primary preclinical literature (HGF/c-Met, synaptogenesis, picomolar potency). (2026)
• Evolutionary.org forum log — proves independent forum-level self-reporting with source skepticism built in.
• ExcelMale thread — proves the safety-concern discussion (c-Met pathway, no trials) is happening in the community, not being suppressed.
• Vendor research guides (SourcePeptides 2026 guide) — synthesize the primary preclinical literature (HGF/c-Met, synaptogenesis, picomolar potency). (2026)
• Community dataset signal — June-2026 GitHub hukus/llimitless scan flags Dihexa as frontier lore with isolated user stories. (2026)
• Community — | Community-cited dose | 1–10 mg/day oral (folklore) | Forum logs — **not medical guidance, no research basis** |

Source URLs were not recorded for these references.